https://www.selleckchem.com/pr....oducts/Pitavastatin-
We conclude that the 80 metabolites and nine metabolic pathways identified might serve as biomarkers to distinguish bipolar disorder patients from healthy controls. To minimize the risk of Progressive Multifocal Leukoencephalopathy and rebound in JCV-positive multiple sclerosis (MS) patients after 24 natalizumab doses, it has been proposed to extend the administrations interval. The objective is to evaluate the EID efficacy on MRI activity compared with the standard interval dosing (SID). Observational, multicentre,
Like
Comment
Share
